Graham Collins, Associate Professor, Haematology and lymphoma specialist at Oxford Cancer and Haematology centre, shared a post on X:
“Real world data from UK – Brexucel RR Mantle cell lymphoma.
- 119 approved, 83 infused.
- PD / manufacturing failure main reasons for non-infusion.
- ORR/CRR 87%/ 81%.
- Med PFS (infused) 21 months.
- NRM 6/12/24months 6/15/25% (infusion mainly).
Active agent but NRM concerning.”
Visit the article website.
Source: Graham Collins/X